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Abstract
Background: Diabetes is known to be associated with cancer of the pancreas, though there is
some debate as to whether it is a cause or a consequence of the disease. We investigated the
incidence of pancreatic cancer in a cohort of 37926 Israeli women followed for 28–40 years for
whom information on diabetes had been collected at the time they gave birth, in 1964–1976, in
Jerusalem. There were 54 cases of pancreatic cancer ascertained from the Israel Cancer Registry
during follow-up.
Methods: We used Cox proportional hazards models to adjust for age at baseline and explore
effects of other risk factors, including ethnic groups, preeclampsia, birth order and birth weight of
offspring.
Results:  W e  ob s e r v e d  n o c a se s of  pa n c r e a t i c  c ancer in the women with insulin dependent
diabetes; however, there were five cases in the women with gestational diabetes. The interval
between the record of diabetes in pregnancy and the diagnosis of pancreatic cancer ranged from
14–35 years. Women with a history of gestational diabetes showed a relative risk of pancreatic
cancer of 7.1 (95% confidence interval, 2.8–18.0).
Conclusion: We conclude that gestational diabetes is strongly related to the risk of cancer of the
pancreas in women in this population, and that gestational diabetes can precede cancer diagnosis
by many years.
Background
Cancer of the pancreas is the fourth highest cause of death
from cancer among women in the US [1]. It is generally
diagnosed at an advanced stage. Only a small proportion
of tumors can be surgically resected [2], and many are
resistant to chemotherapy or radiation [2,3]. Thus, the
lethality of pancreatic cancer is high, with the mortality
rate (9.2/100000) approximating the incidence rate (9.5/
100000) among women [4]. Diabetes is well known to be
associated with pancreatic cancer [5,6]. There has been a
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long-standing debate, however, as to whether this is a con-
sequence or an antecedent of the pancreatic tumor; evi-
dence exists supporting both views [3]. On the one hand,
patients with newly diagnosed pancreatic cancer fre-
quently have type 2 diabetes mellitus of recent onset;
removal of the tumor often ameliorates its manifestations
[3]. On the other hand, individuals with long-standing
diabetes have also been shown to be at increased risk of
pancreatic cancer [3].
During pregnancy, women become progressively more
insulin resistant as a result of weight gain and release of
placental hormones [7]. While most women are able to
compensate with increased secretion of insulin and expe-
rience only minor changes in plasma glucose levels, those
with gestational diabetes mellitus are unable to compen-
sate for the increased resistance and become hyperglyc-
emic [7]. Risk factors for gestational diabetes mellitus
include older age, family history of diabetes and high
body mass index (BMI) and ethnicity [8]. In the US, the
prevalence of gestational diabetes mellitus is approxi-
mately 7% [9], though it varies by ethnic group. It is more
common among African-Americans, Hispanics, Asians
and Native Americans than among non-Hispanic Whites
[10-14]. Short-term consequences include fetal macro-
somia and other neonatal morbidities; long term sequelae
place the mother and offspring at increased risk of type 2
diabetes mellitus [9]. A few investigators have studied ges-
tational diabetes mellitus and gestational glucose intoler-
ance as risk factors for breast cancer and other cancers
[15,16] but none, to our knowledge, have investigated
gestational diabetes mellitus in relation to pancreatic can-
cer.
Methods
This study relies on an ongoing population-based cohort
study derived from births, with follow-up till the present
day of all offspring and their parents. The Jerusalem Peri-
natal Study recorded all 92408 births in 1964–1976 to
residents of a defined geographic area. Subsets of mothers
were interviewed in 1965–1968 (N = 11467 births) in
antenatal clinics and in 1974–1976 (N = 16912 births) 1–
3 days after birth [17]. The present analysis focuses on the
mothers of the 84781 offspring born in the three largest
obstetric units, where the study included active surveil-
lance of maternal and obstetric conditions; data on mater-
nal and obstetric information was copied from the labor
ward log at the time of birth using separate rubrics in the
Perinatal Study's pre-coded forms [17] that allowed for a
record of maternal "diabetes" (presumed to be insulin-
dependent juvenile diabetes or type 1) and "pre-diabetes",
corresponding, approximately, to gestational diabetes
mellitus. In that era, all pregnant women were screened
for glycosuria at each antenatal visit; if found positive,
they would be referred for an oral glucose tolerance test.
In 2004–2005, using the national identity numbers that
are assigned to citizens of Israel, we traced and ascertained
the vital status of 40898 mothers in this cohort through
linkage with Israel's National Population Registry. Then,
we linked the cohort to the Israel Cancer Registry. The
Israel Cancer Registry, which was started in 1961, is 95.7%
complete for pancreatic cancer [18]. Names, identity
numbers and other identifying information were removed
from the file that was analyzed collaboratively in New
York and Israel. The study was approved by the Institu-
tional Review Boards of both participating institutions.
Statistical analyses
We included all cases of first primary malignant pancre-
atic cancers, as defined by the International Classification
of Diseases for Oncology, 3rd edition (site code: C25 and
fifth digit morphology code of 3) that were diagnosed
between the first observed birth and 31 December 2004.
We used Cox proportional hazards models to estimate the
relative risk (hazard ratio) of pancreatic cancer in women
with a diagnosis of gestational diabetes mellitus in any
pregnancy compared to women without a diagnosis of
gestational diabetes mellitus during the entire study
period (1964–1976) using the PHREG procedure availa-
ble in SAS 9.0 (SAS Institute Inc, Cary, NC, USA). Women
were followed from the "baseline birth" (i.e., first time
they gave birth in 1964–1976) until death, date of diagno-
sis of any cancer, or end of follow-up period (31 Decem-
ber 2004).
Variables included in the model were those that altered
the age-adjusted estimate of the relative risk by more than
10%. We also tested whether a covariate for time period
(year of first observed birth) affected the estimate, or was
predictive of pancreatic cancer risk. As it did not effect the
estimate and did not predict pancreatic cancer risk, we did
not include the term in the final model. Age at the first
observed birth was treated as a continuous variable, miss-
ing values (N = 50) being assigned to the mean (26.2
years). Other variables were treated as dichotomies, or sets
with a dummy, coded 1 (if present) or 0 (if absent). Vari-
ables tested included categories of birth order at the last
observed pregnancy, ethnic ancestry based on the
woman's father's place of birth (Israel, other Western Asia,
North Africa and Europe etc. – the latter including the
Americas, sub-Saharan Africa and Australasia; no infor-
mation was available for the origin of the woman's
mother), social class (based on husband's occupation at
last observed birth), categories of education, presence of
other specific complications of pregnancy in any observed
birth, and birth defects, low (< 2.5 kg) or high (4.0 kg or
more) birth weight in one or more offspring. Unless oth-
erwise stated, categories of missing data in other variables
(most affected less than 0.1% of women) were included in
the reference groups. The results are presented as relativeBMC Medicine 2007, 5:25 http://www.biomedcentral.com/1741-7015/5/25
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risks, adjusted for age or for other variables, with 95%
confidence intervals.
Numbers and exclusions
Of the 40898 women traced, 37980 (92.9%) delivered at
least once in one of the three largest hospitals in Jerusa-
lem, where complete diabetes information was collected
for the cohort. Untraced women were similar in age at first
observed birth, more often unmarried and more likely to
be of European ancestry. Untraced women had a lower
prevalence of gestational diabetes mellitus (0.4%) com-
pared to a prevalence of 1.0% among women who were
traced. Among women who were successfully traced, the
incidence of pancreatic cancer was not significantly
related to hospital of birth. We also excluded 41 women
who were diagnosed with various malignancies prior to
their first observed birth in the study, and an additional
13 women (none with pancreas cancer) who were diag-
nosed with gestational diabetes mellitus in one pregnancy
and type 1 diabetes mellitus in another pregnancy during
the study period.
Results
The assumption of proportionality over time was met
based on a visual inspection of log negative log survival
plot. There were 37926 women available for study,
including 410 diagnosed with gestational diabetes during
one or more pregnancies in 1964–1976. Table 1 compares
the characteristics of women with and without this preg-
nancy complication. Women with gestational diabetes
tended to be older at the baseline birth, multiparous at the
last birth and of slightly higher social class. While there
were subtle differences in ethnic ancestry (women with
gestational diabetes mellitus being more likely to have a
father from Europe), immigrant women were similar to
those born in Israel. Several complications of pregnancy
were significantly more frequent among women with ges-
tational diabetes mellitus (e.g. heart disease and preec-
lampsia) and sub-optimal outcomes were more common
in their offspring, including low birth weight, high birth
weight and congenital malformations.
At the cut-off date of 31 December 2004, the mean length
of follow-up was 38.0 years and the median age of the
women in the cohort was 59 (43–94). During the 28–40
Table 1: Percent distribution of women with and without a history of gestational diabetes, by selected variables
Characteristic Gestational diabetes p-Value
-+
Number of women 37516 410
Percent 100 100




Birth place of woman Born in Israel 46.8 47.8 0.7
Born abroad 53.2 52.2
Birth place of woman's father Israel 14.6 11.5 0.05
Other West Asia 28.3 27.6
North Africa 21.5 19.5
Europe etc. 35.5 41.5
Social class at last observed birth Low 30.8 25.6 0.03
Middle 37.2 42.7
High 32.0 31.7
Heart disease at any observed birth No 99.3 96.8 < 0.0001
Yes 0.7 3.2
Preeclampsia at any observed birth No 97.2 87.8 < 0.0001
Yes 2.8 12.2
Birth order at last observed birth 1 22.1 11.7 < 0.0001
2–3 44.7 48.5
4+ 33.2 39.8
Any offspring with birth weight ≤4000 g No 88.7 73.7 < 0.0001
Yes 11.3 26.3
Any offspring with birth weight < 2500 g No 89.0 80.0 < 0.0001
Yes 11.0 20.0
Any offspring with congenital 
malformations
No 92.5 88.3 0.001
Yes 7.5 11.7BMC Medicine 2007, 5:25 http://www.biomedcentral.com/1741-7015/5/25
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years of follow-up, 54 cases of pancreatic cancer were
reported to the Israel Cancer Registry in the cohort. The
interval between diagnosis of gestational diabetes melli-
tus and diagnosis of pancreatic cancer ranged from 14–35
years. The median age at diagnosis of pancreatic cancer
was 57 (range 35–77); among those women who were
also diagnosed with gestational diabetes mellitus, the
median age at diagnosis was 58 (range 42–76). The life-
table estimates of 1-year and 5-year survival rates of these
cases were 30% and 8%, respectively.
Table 2 shows the association of selected variables with
the relative risk of pancreatic cancer, adjusted for age at
entry. Immigrants did not differ from Israeli-born women
and although there were differences associated with eth-
nic origin. The lowest incidence of pancreas cancer was
seen in women whose fathers were born in North Africa
or Israel. Though the middle and lowest social classes,
compared to the highest social class, were at increased risk
of pancreatic cancer, the estimates did not reach the level
of significance.
There was a sevenfold increase in risk estimated for
women reported to have heart disease in at least one of
their pregnancies (p < 0.0008), based on three cases.
Other complications of pregnancy (i.e., preeclampsia, low
birth weight, high birth weight and birth defects and high
birth order) were associated with modest (non-signifi-
cant) increases in the incidence of pancreatic cancer.
Type 1 diabetes was reported at the time of birth in 137
women; none of these were subsequently diagnosed with
pancreatic cancer during the follow-up period. Among the
410 women with gestational diabetes, five were diagnosed
with pancreatic cancer. Table 3 shows estimates of the rel-
ative risk of this malignancy in women previously diag-
nosed with gestational diabetes mellitus, both age-
adjusted and further adjusted for other variables. There
was a highly significant eightfold increase in incidence
when taking age into account; this excess was maintained
sevenfold and was also highly significant after adjusting
for other risk factors such as birth of offspring with espe-
cially low or high birth weights.
Discussion
To our knowledge this is the first study to relate pancreatic
cancer in women to gestational diabetes mellitus. The
results suggest that gestational diabetes mellitus could be
an important risk factor for pancreatic cancer. Unlike type
2 diabetes mellitus, gestational diabetes mellitus has been
little studied as a risk factor for cancer. In a population-
based case control study that examined pregnancy charac-
Table 2: Incidence of pancreatic cancer, age-adjusted relative risk (RR) and 95 % confidence interval (CI) by selected characteristics
Pancreatic cancer
Characteristic - + RR 95% CI
Number of women 37872 54
Birthplace of woman Born abroad 20136 33 1
Born in Israel 17736 21 1 0.6–1.8
Maternal father's country of birth Israel 5535 4 0.4 0.1–1.2
Other West Asia 10720 21 0.9 0.5–1.7
North Africa 8136 6 0.4 0.2–0.9
Europe 13481 23 1
Social class High 12141 9 1
Middle 14099 23 2.1 1.0–4.5
Low 11632 22 1.7 0.8–3.7
Birth order at last observed birth 1–2 17664 13 1
3+ 20208 41 1.3 0.7–2.6
Heart disease in any observed birth No 37598 51 1
Yes 274 3 7.3 2.3–23.4
Preeclampsia in any observed birth No 36774 51 1
Yes 1098 3 1.4 0.4–4.7
Offspring ≥ 4000 g at birth in any 
observed birth
No 33529 43 1
Yes 4343 11 1.7 0.9–3.3
Offspring < 2500 g at birth in any 
observed birth
No 33679 45 1
Yes 4193 9 1.7 0.8–3.5
Offspring with congenital 
malformations in any observed birth
No 35016 48 1
Yes 2856 6 1.6 0.7–3.8BMC Medicine 2007, 5:25 http://www.biomedcentral.com/1741-7015/5/25
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teristics and breast cancer, it was reported that the risk
associated with gestational diabetes mellitus was reduced
in the first five years after pregnancy but somewhat
increased after five years [15]. A prospective cohort study
in Scotland studied indices of sub-clinical glucose intoler-
ance among women recruited during pregnancy, relating
them to cancer 20 years later [16]. The risk of any neo-
plasm increased with higher fasting plasma glucose levels.
Similar results were found for breast cancer. Though that
study was quite small (N = 753), it suggested that even
subclinical gestational glucose intolerance might be an
important determinate of cancer risk.
The conversion rate for gestational diabetes mellitus to
type 2 diabetes mellitus can be as high as 70% (range 2.6–
70%) depending on the length of follow-up [19]. Women
who have had gestational diabetes mellitus are often more
insulin resistant than their normal counterparts after preg-
nancy and have also been found to have a defect in β-cell
function (reviewed in Buchanan [7]). Increasing insulin
resistance coupled with a decrease in β-cell function over
time could lead to hyperglycemia characteristic of type 2
diabetes mellitus.
Several studies have investigated the role of glucose levels
and risk of pancreatic cancer. A prospective study (follow-
up 12 years) in Chicago found that mean post-load
plasma glucose levels were lower among women who sub-
sequently died of pancreatic cancer compared to survi-
vors, though there were only six deaths reported [20].
Another study in the same population in Chicago (aver-
age follow-up of 25 years), examined post-load plasma
glucose levels in 15183 women, relating them to pancre-
atic cancer mortality [21]. The authors reported a non-sig-
nificant increase in deaths from this cause associated with
post-load plasma glucose levels above 119 mg/dl. In a
prospective study among 468615 Korean women enrolled
in a health plan and followed for up to 10 years, mortality
from pancreatic cancer was associated with a significant
increase in risk among women with fasting serum glucose
levels above 90 mg/dl (p = 0.01) [22]. The relative risk
(compared to < 90 mg/dl) of fasting serum glucose in the
normal range (90–109 mg/dl) was 1.5 (95% confidence
interval (CI) 1.2–1.8) and up to 2.1 (95% CI 1.4–2.9) for
those ≥ 126 mg/dl; the findings were similar when exam-
ining the association between fasting serum glucose levels
and the incidence of pancreatic cancer. The results of the
study in Korea suggest, as did the study in Scotland [16],
that even glucose levels in the upper range of normal
could be associated with an increased risk of some can-
cers, including pancreatic cancer.
There is a pathway by which hyperglycemia could increase
the risk of pancreatic cancer in persons with either type 1
or type 2 diabetes mellitus. Hyperglycemia increases the
generation of reactive oxygen species (ROS) that are
hypothesized to be linked to some of the more common
morbidities associated with diabetes [23]. Persons with
type I and type 2 diabetes mellitus have been reported to
generate more reactive oxygen species (ROS) than con-
trols [24]. If anti-oxidant mechanisms are overwhelmed
and DNA is damaged, this could lead to the loss of func-
tion in critical proteins such as those involved in tumor
suppression. However, it should be considered that in our
sample only women diagnosed with gestational diabetes
mellitus went on to develop pancreatic cancer whereas no
cases of pancreatic cancer were found among women
diagnosed with type 1 diabetes mellitus.
Gapstur and colleagues have proposed a mechanism by
which hyperinsulemia, associated with type 2 diabetes
mellitus, might act to increase the risk of pancreatic cancer
[21]. They postulate that in the hyperinsulemic state, the
exocrine cells of the pancreas are exposed to extremely
high levels of insulin. Insulin at high levels binds to the
insulin-like growth factor I (IGF1) receptor [25] and
downregulates the IGF binding protein 1, (IGFBP1) [26],
thus the amount of bioavailable IGF-1 could increase.
Insulin has been reported to increase cell growth in pan-
creatic cancer cell lines [27], while IGF1 has been shown
to increase pancreatic cancer cell growth [28].
For many years there has been a controversy whether dia-
betes is causally associated with pancreatic cancer or is
merely a consequence of tumor growth. Different studies
have addressed this question by examining the length of
Table 3: Numbers of women with and without pancreatic cancer, relative risk (RR) and 95% confidence interval (CI) by gestational 
diabetes
Characteristic Pancreatic cancer Age-adjusted RR 95% CI p-Value RR* 95% CI p-Value
-+
Number of women 37872 54
Gestational diabetes:
- 37467 49 1 1
+ 405 5 7.9 3.1–19.8 < 0.0001 7.1 2.8–18.0 < 0.0001
* RR adjusted for age at first observed birth and birth weight.BMC Medicine 2007, 5:25 http://www.biomedcentral.com/1741-7015/5/25
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time between diagnosis of diabetes and pancreatic cancer.
In a recent meta-analysis, time between diagnoses was
examined; it was reported that there was a significant 50%
increase in risk associated with type 2 diabetes mellitus
diagnosed 5 or more years earlier [6]. In the current study
the time between diagnosis of gestational diabetes melli-
tus and that of pancreatic cancer ranged from 14–35 years.
As disease progression is aggressive in pancreatic cancer
(the 1-year survival rate was 30% in this cohort) it makes
it unlikely that gestational diabetes diagnosed 14 or more
years earlier is a consequence of tumor growth [6].
An intriguing observation is the strong association of pan-
creatic cancer with heart disease. Although based on only
three cases, it is unlikely to be due to chance. We have no
information on the exact diagnosis; however, heart dis-
ease recorded at the time of the birth would have been due
to congenital defect, rheumatic heart disease or cardiomy-
opathy.
Our study has the advantage of a prospective design, long
follow-up and complete obstetric history on all births.
The data on gestational diabetes mellitus and other birth
complications were taken from medical records at the
time of birth and did not rely on self-report. Further, the
ascertainment of pancreatic cancer is likely to be complete
and unbiased relative to the obstetric history. Unlike
many studies of diabetes, we were able to distinguish
between women with type 1 diabetes mellitus and those
with gestational diabetes mellitus; however, we do not
have an exact definition of diabetes and modern criteria
for gestational diabetes mellitus were not applied in that
era. Data were available only on observed pregnancies,
and there might be some misclassification of exposure,
but it was likely random and would only tend to weaken
the association. We were unable to control for smoking
history and body mass index in the analysis; however, the
prevalence of current smoking and obesity in a subgroup
of women interviewed postpartum was only 13.2% and
2.1% respectively. Though there were only 54 cases of
pancreatic cancer ascertained through the follow-up
period, given the strength of the association our results are
unlikely to be due to chance or confounding, although it
cannot be ruled out as the RR at the low end of the confi-
dence interval was 2.8.
Conclusion
The prevalence of gestational diabetes mellitus is reported
to be increasing [29,30], not surprisingly given the preva-
lence of overweight and obesity in the US [31]. Other than
type 2 diabetes mellitus, the sequelae of gestational diabe-
tes mellitus remains largely unknown. If the results of the
current study are confirmed, then it would be expected
that the incidence of pancreatic cancer could increase.
Research is urgently needed to ascertain this, and other
possible health sequelae of gestational diabetes mellitus,
so that appropriate interventions can be developed and
implemented.
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